Tegileridine is a drug which acts as a μ-opioid receptor agonist.

It is closely related to compounds such as oliceridine, TRV734, and SHR9352, and shares a similar profile as a biased agonist selective for activation of the G-protein signalling pathway over β-arrestin 2 recruitment.

[1] In January 2024, tegileridine was approved in China for the treatment of moderate to severe pain after abdominal surgery.

This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.